메뉴 건너뛰기




Volumn 21, Issue 6, 2011, Pages 305-313

The benefits of growth hormone therapy in patients with Turner syndrome, Noonan syndrome and children born small for gestational age

Author keywords

Adherence; Growth hormone; Noonan syndrome; Short children born small for gestational age; Subcutaneous injection; Turner syndrome

Indexed keywords

GROWTH HORMONE; OXANDROLONE; PLACEBO;

EID: 80055087398     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2011.09.004     Document Type: Review
Times cited : (29)

References (137)
  • 1
    • 0242270859 scopus 로고    scopus 로고
    • Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee
    • Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee
    • Wilson T.A., Rose S.R., Cohen P., et al. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J. Pediatr. 2003, 143:415-421. Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee.
    • (2003) J. Pediatr. , vol.143 , pp. 415-421
    • Wilson, T.A.1    Rose, S.R.2    Cohen, P.3
  • 2
    • 0027445119 scopus 로고
    • Adherence to treatment and health outcomes
    • Horwitz R.I., Horwitz S.M. Adherence to treatment and health outcomes. Arch. Intern. Med. 1993, 153:1863-1868.
    • (1993) Arch. Intern. Med. , vol.153 , pp. 1863-1868
    • Horwitz, R.I.1    Horwitz, S.M.2
  • 3
    • 33947501922 scopus 로고    scopus 로고
    • Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society
    • Clayton P.E., Cianfarani S., Czernichow P., Johannsson G., Rapaport R., Rogol A. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J. Clin. Endocrinol. Metab. 2007, 92:804-810.
    • (2007) J. Clin. Endocrinol. Metab. , vol.92 , pp. 804-810
    • Clayton, P.E.1    Cianfarani, S.2    Czernichow, P.3    Johannsson, G.4    Rapaport, R.5    Rogol, A.6
  • 4
    • 0028889404 scopus 로고
    • Growth in full-term small-for-gestational-age infants: from birth to final height
    • Karlberg J., Albertsson-Wikland K. Growth in full-term small-for-gestational-age infants: from birth to final height. Pediatr. Res. 1995, 38:733-939.
    • (1995) Pediatr. Res. , vol.38 , pp. 733-939
    • Karlberg, J.1    Albertsson-Wikland, K.2
  • 5
    • 0030049115 scopus 로고    scopus 로고
    • (Erratum in:)
    • Pediatr. Res. 1996, 39:175. (Erratum in:).
    • (1996) Pediatr. Res. , vol.39 , pp. 175
  • 6
    • 0030815994 scopus 로고    scopus 로고
    • Reduced final height and indications for insulin resistance in 20year olds born small for gestational age: regional cohort study
    • Leger J., Levy-Marchal C., Bloch J., et al. Reduced final height and indications for insulin resistance in 20year olds born small for gestational age: regional cohort study. BMJ 1997, 315:341-347.
    • (1997) BMJ , vol.315 , pp. 341-347
    • Leger, J.1    Levy-Marchal, C.2    Bloch, J.3
  • 7
    • 0031792808 scopus 로고    scopus 로고
    • Human growth hormone treatment of short-stature children born small for gestational age: effect on muscle and adipose tissue mass during a 3-year treatment period and after 1year's withdrawal
    • Leger J., Garel C., Fjellestad-Paulsen A., Hassan M., Czernichow P. Human growth hormone treatment of short-stature children born small for gestational age: effect on muscle and adipose tissue mass during a 3-year treatment period and after 1year's withdrawal. J. Clin. Endocrinol. Metab. 1998, 83:3512-3516.
    • (1998) J. Clin. Endocrinol. Metab. , vol.83 , pp. 3512-3516
    • Leger, J.1    Garel, C.2    Fjellestad-Paulsen, A.3    Hassan, M.4    Czernichow, P.5
  • 8
    • 0030965815 scopus 로고    scopus 로고
    • The timing of early postnatal catch-up growth in normal, full-term infants born short for gestational age
    • Karlberg J.P., Albertsson-Wikland K., Kwan E.Y., Lam B.C., Low L.C. The timing of early postnatal catch-up growth in normal, full-term infants born short for gestational age. Horm. Res. 1997, 48(Suppl. 1):17-24.
    • (1997) Horm. Res. , vol.48 , Issue.SUPPL. 1 , pp. 17-24
    • Karlberg, J.P.1    Albertsson-Wikland, K.2    Kwan, E.Y.3    Lam, B.C.4    Low, L.C.5
  • 10
    • 78651456867 scopus 로고    scopus 로고
    • Auxological and metabolic study in small for gestational age children during 2years follow-up
    • Polo Perucchin P., Traggiai C., Calevo M.G., et al. Auxological and metabolic study in small for gestational age children during 2years follow-up. J. Matern.-Fetal Neonatal Med. 2011, 24:381-387.
    • (2011) J. Matern.-Fetal Neonatal Med. , vol.24 , pp. 381-387
    • Polo Perucchin, P.1    Traggiai, C.2    Calevo, M.G.3
  • 11
    • 3343026199 scopus 로고    scopus 로고
    • Turner syndrome: evaluation of prenatal diagnosis in 19 European registries
    • Baena N., De Vigan C., Cariati E., et al. Turner syndrome: evaluation of prenatal diagnosis in 19 European registries. Am. J. Med. Genet. A 2004, 15:16-20.
    • (2004) Am. J. Med. Genet. A , vol.15 , pp. 16-20
    • Baena, N.1    De Vigan, C.2    Cariati, E.3
  • 12
    • 0018069955 scopus 로고
    • Spontaneous deaths of fetuses with chromosomal abnormalities diagnosed prenatally
    • Hook E.B. Spontaneous deaths of fetuses with chromosomal abnormalities diagnosed prenatally. N. Engl. J. Med. 1978, 299:1036-1038.
    • (1978) N. Engl. J. Med. , vol.299 , pp. 1036-1038
    • Hook, E.B.1
  • 13
    • 0025542292 scopus 로고
    • Sex chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark
    • Nielsen J., Wohlert M. Sex chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark. Birth Defects Orig. Artic. Ser. 1990, 26:209-223.
    • (1990) Birth Defects Orig. Artic. Ser. , vol.26 , pp. 209-223
    • Nielsen, J.1    Wohlert, M.2
  • 14
    • 0035963921 scopus 로고    scopus 로고
    • Turner's syndrome
    • Ranke M.B., Saenger P. Turner's syndrome. Lancet 2001, 358:309-314.
    • (2001) Lancet , vol.358 , pp. 309-314
    • Ranke, M.B.1    Saenger, P.2
  • 15
    • 27144487822 scopus 로고    scopus 로고
    • Improved final height with long-term growth hormone treatment in Noonan syndrome
    • Osio D., Dahlgren J., Wikland K.A., Westphal O. Improved final height with long-term growth hormone treatment in Noonan syndrome. Acta Paediatr. 2005, 94:1232-1237.
    • (2005) Acta Paediatr. , vol.94 , pp. 1232-1237
    • Osio, D.1    Dahlgren, J.2    Wikland, K.A.3    Westphal, O.4
  • 17
    • 0028077697 scopus 로고
    • Mapping a gene for Noonan syndrome to the long arm of chromosome 12
    • Jamieson C.R., van der Burgt I., Brady A.F., et al. Mapping a gene for Noonan syndrome to the long arm of chromosome 12. Nat. Genet. 1994, 8:357-360.
    • (1994) Nat. Genet. , vol.8 , pp. 357-360
    • Jamieson, C.R.1    van der Burgt, I.2    Brady, A.F.3
  • 18
    • 18444401014 scopus 로고    scopus 로고
    • Noonan syndrome and related disorders: genetics and pathogenesis
    • Tartaglia M., Gelb B.D. Noonan syndrome and related disorders: genetics and pathogenesis. Annu. Rev. Genomics Hum. Genet. 2005, 6:45-68.
    • (2005) Annu. Rev. Genomics Hum. Genet. , vol.6 , pp. 45-68
    • Tartaglia, M.1    Gelb, B.D.2
  • 19
    • 33845900943 scopus 로고    scopus 로고
    • Germline gain-of-function mutations in SOS1 cause Noonan syndrome
    • Roberts A.E., Araki T., Swanson K.D., et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat. Genet. 2007, 39:70-74.
    • (2007) Nat. Genet. , vol.39 , pp. 70-74
    • Roberts, A.E.1    Araki, T.2    Swanson, K.D.3
  • 20
    • 34547530823 scopus 로고    scopus 로고
    • Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy
    • Pandit B., Sarkozy A., Pennacchio L.A., et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat. Genet. 2007, 39:1007-1012.
    • (2007) Nat. Genet. , vol.39 , pp. 1007-1012
    • Pandit, B.1    Sarkozy, A.2    Pennacchio, L.A.3
  • 21
    • 80055098242 scopus 로고    scopus 로고
    • Spectrum of mutations in Noonan syndrome and their correlation with phenotypes
    • [Epub ahead of print]
    • Lee B.H., Kim J.M., Jin H.Y., Kim G.H., Choi J.H., Yoo H.W. Spectrum of mutations in Noonan syndrome and their correlation with phenotypes. J. Pediatr. 2011, (July 22). [Epub ahead of print].
    • (2011) J. Pediatr. , Issue.2
    • Lee, B.H.1    Kim, J.M.2    Jin, H.Y.3    Kim, G.H.4    Choi, J.H.5    Yoo, H.W.6
  • 23
    • 0000040232 scopus 로고    scopus 로고
    • Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society
    • Growth Hormone Research Society
    • Growth Hormone Research Society Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J. Clin. Endocrinol. Metab. 2000, 85:3990-3993.
    • (2000) J. Clin. Endocrinol. Metab. , vol.85 , pp. 3990-3993
  • 24
    • 0036772809 scopus 로고    scopus 로고
    • Diagnosis and management of growth hormone deficiency in childhood and adolescence - part 2: growth hormone treatment in growth hormone deficient children
    • Tanaka T., Cohen P., Clayton P.E., Laron Z., Hintz R.L., Sizonenko P.C. Diagnosis and management of growth hormone deficiency in childhood and adolescence - part 2: growth hormone treatment in growth hormone deficient children. Growth Horm. IGF Res. 2002, 12:323-341.
    • (2002) Growth Horm. IGF Res. , vol.12 , pp. 323-341
    • Tanaka, T.1    Cohen, P.2    Clayton, P.E.3    Laron, Z.4    Hintz, R.L.5    Sizonenko, P.C.6
  • 25
    • 0029085354 scopus 로고
    • Spontaneous 24-hour growth hormone profiles in prepubertal small for gestational age children
    • Boguszewski M., Rosberg S., Albertsson-Wikland K. Spontaneous 24-hour growth hormone profiles in prepubertal small for gestational age children. J. Clin. Endocrinol. Metab. 1995, 80:2599-2606.
    • (1995) J. Clin. Endocrinol. Metab. , vol.80 , pp. 2599-2606
    • Boguszewski, M.1    Rosberg, S.2    Albertsson-Wikland, K.3
  • 26
    • 70649088097 scopus 로고    scopus 로고
    • Changes in GH/IGF-1 axis in intrauterine growth retardation: consequences of fetal programming?
    • Setia S., Sridhar M.G. Changes in GH/IGF-1 axis in intrauterine growth retardation: consequences of fetal programming?. Horm. Metab. Res. 2009, 41:791-798.
    • (2009) Horm. Metab. Res. , vol.41 , pp. 791-798
    • Setia, S.1    Sridhar, M.G.2
  • 28
    • 0038699006 scopus 로고    scopus 로고
    • Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomized controlled study
    • Carel J.C., Chatelain P., Rochiccioli P., Chaussain J.L. Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomized controlled study. J. Clin. Endocrinol. Metab. 2003, 88:1587-1593.
    • (2003) J. Clin. Endocrinol. Metab. , vol.88 , pp. 1587-1593
    • Carel, J.C.1    Chatelain, P.2    Rochiccioli, P.3    Chaussain, J.L.4
  • 29
    • 0041883362 scopus 로고    scopus 로고
    • Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial
    • van Pareren Y., Mulder P., Houdijk M., Jansen M., Reeser M., Hokken-Koelega A. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial. J. Clin. Endocrinol. Metab. 2003, 88:3584-3590.
    • (2003) J. Clin. Endocrinol. Metab. , vol.88 , pp. 3584-3590
    • van Pareren, Y.1    Mulder, P.2    Houdijk, M.3    Jansen, M.4    Reeser, M.5    Hokken-Koelega, A.6
  • 30
    • 0034864154 scopus 로고    scopus 로고
    • Treatment with growth hormone in short children born with intrauterine growth retardation
    • Czernichow P. Treatment with growth hormone in short children born with intrauterine growth retardation. Endocrine 2001, 15:39-42.
    • (2001) Endocrine , vol.15 , pp. 39-42
    • Czernichow, P.1
  • 31
    • 0033305332 scopus 로고    scopus 로고
    • Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial
    • Sas T., de Waal W., Mulder P., et al. Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial. J. Clin. Endocrinol. Metab. 1999, 84:3064-3070.
    • (1999) J. Clin. Endocrinol. Metab. , vol.84 , pp. 3064-3070
    • Sas, T.1    de Waal, W.2    Mulder, P.3
  • 32
    • 56749097072 scopus 로고    scopus 로고
    • European multicentre study in children born small for gestational age with persistent short stature: comparison of continuous and discontinuous growth hormone treatment regimens
    • European Norditropin SGA Study Group
    • Phillip M., Lebenthal Y., Lebl J., et al. European multicentre study in children born small for gestational age with persistent short stature: comparison of continuous and discontinuous growth hormone treatment regimens. Horm. Res. 2009, 71:52-59. European Norditropin SGA Study Group.
    • (2009) Horm. Res. , vol.71 , pp. 52-59
    • Phillip, M.1    Lebenthal, Y.2    Lebl, J.3
  • 33
    • 0029820179 scopus 로고    scopus 로고
    • Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age
    • Boguszewski M., Jansson C., Rosberg S., Albertsson-Wikland K. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age. J. Clin. Endocrinol. Metab. 1996, 81:3902-3908.
    • (1996) J. Clin. Endocrinol. Metab. , vol.81 , pp. 3902-3908
    • Boguszewski, M.1    Jansson, C.2    Rosberg, S.3    Albertsson-Wikland, K.4
  • 34
    • 0036145971 scopus 로고    scopus 로고
    • High-dose growth hormone (GH) treatment in non-GH-deficient children born small for gestational age induces growth responses related to pretreatment GH secretion and associated with a reversible decrease in insulin sensitivity
    • de Zegher F., Ong K., van Helvoirt M., Mohn A., Woods K., Dunger D. High-dose growth hormone (GH) treatment in non-GH-deficient children born small for gestational age induces growth responses related to pretreatment GH secretion and associated with a reversible decrease in insulin sensitivity. J. Clin. Endocrinol. Metab. 2002, 87:148-151.
    • (2002) J. Clin. Endocrinol. Metab. , vol.87 , pp. 148-151
    • de Zegher, F.1    Ong, K.2    van Helvoirt, M.3    Mohn, A.4    Woods, K.5    Dunger, D.6
  • 35
    • 10744222957 scopus 로고    scopus 로고
    • GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: 3-year results of a randomized, controlled GH trial
    • Arends N.J., Boonstra V.H., Mulder P.G., et al. GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: 3-year results of a randomized, controlled GH trial. Clin. Endocrinol. (Oxf.) 2003, 59:779-787.
    • (2003) Clin. Endocrinol. (Oxf.) , vol.59 , pp. 779-787
    • Arends, N.J.1    Boonstra, V.H.2    Mulder, P.G.3
  • 36
    • 1542313860 scopus 로고    scopus 로고
    • Effect of different growth hormone dosages on the growth velocity in children born small for gestational age
    • Bozzola E., Lauriola S., Messina M.F., Bona G., Tinelli C., Tatò L. Effect of different growth hormone dosages on the growth velocity in children born small for gestational age. Horm. Res. 2004, 61:98-102.
    • (2004) Horm. Res. , vol.61 , pp. 98-102
    • Bozzola, E.1    Lauriola, S.2    Messina, M.F.3    Bona, G.4    Tinelli, C.5    Tatò, L.6
  • 37
    • 22544440483 scopus 로고    scopus 로고
    • Growth hormone therapy for children born small for gestational age: height gain is less dose dependent over the long term than over the short term
    • de Zegher F., Hokken-Koelega A. Growth hormone therapy for children born small for gestational age: height gain is less dose dependent over the long term than over the short term. Pediatrics 2005, 115:e458-e462.
    • (2005) Pediatrics , vol.115
    • de Zegher, F.1    Hokken-Koelega, A.2
  • 38
    • 0037241082 scopus 로고    scopus 로고
    • Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database)
    • KIGS International Board
    • Ranke M.B., Lindberg A., Cowell C.T., et al. Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database). J. Clin. Endocrinol. Metab. 2003, 88:125-131. KIGS International Board.
    • (2003) J. Clin. Endocrinol. Metab. , vol.88 , pp. 125-131
    • Ranke, M.B.1    Lindberg, A.2    Cowell, C.T.3
  • 39
    • 12844263377 scopus 로고    scopus 로고
    • Final height in short children born small for gestational age treated with growth hormone
    • Dahlgren J., Wikland K.A. Final height in short children born small for gestational age treated with growth hormone. Pediatr. Res. 2005, 57:216-222.
    • (2005) Pediatr. Res. , vol.57 , pp. 216-222
    • Dahlgren, J.1    Wikland, K.A.2
  • 40
    • 0034458088 scopus 로고    scopus 로고
    • Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6years
    • de Zegher F., Albertsson-Wikland K., Wollmann H.A., et al. Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6years. J. Clin. Endocrinol. Metab. 2000, 85:2816-2821.
    • (2000) J. Clin. Endocrinol. Metab. , vol.85 , pp. 2816-2821
    • de Zegher, F.1    Albertsson-Wikland, K.2    Wollmann, H.A.3
  • 41
    • 0033756754 scopus 로고    scopus 로고
    • Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency
    • Sas T., Mulder P., Hokken-Koelega A. Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. J. Clin. Endocrinol. Metab. 2000, 85:3786-3792.
    • (2000) J. Clin. Endocrinol. Metab. , vol.85 , pp. 3786-3792
    • Sas, T.1    Mulder, P.2    Hokken-Koelega, A.3
  • 42
    • 0034492473 scopus 로고    scopus 로고
    • Body proportions during 6 years of GH treatment in children with short stature born small for gestational age participating in a randomised, double-blind, dose-response trial
    • Sas T.C., Gerver W.J., De Bruin R., et al. Body proportions during 6 years of GH treatment in children with short stature born small for gestational age participating in a randomised, double-blind, dose-response trial. Clin. Endocrinol. (Oxf.) 2000, 53:675-681.
    • (2000) Clin. Endocrinol. (Oxf.) , vol.53 , pp. 675-681
    • Sas, T.C.1    Gerver, W.J.2    De Bruin, R.3
  • 43
    • 34547765996 scopus 로고    scopus 로고
    • Free/dissociable insulin-like growth factor (IGF)-I, not total IGF-I, correlates with growth response during growth hormone treatment in children born small for gestational age
    • Bannink E.M., van Doorn J., Mulder P.G., Hokken-Koelega A.C. Free/dissociable insulin-like growth factor (IGF)-I, not total IGF-I, correlates with growth response during growth hormone treatment in children born small for gestational age. J. Clin. Endocrinol. Metab. 2007, 92:2992-3000.
    • (2007) J. Clin. Endocrinol. Metab. , vol.92 , pp. 2992-3000
    • Bannink, E.M.1    van Doorn, J.2    Mulder, P.G.3    Hokken-Koelega, A.C.4
  • 44
    • 33846094114 scopus 로고    scopus 로고
    • Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (SGA) and untreated short SGA controls
    • van Dijk M., Bannink E.M., van Pareren Y.K., Mulder P.G., Hokken-Koelega A.C. Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (SGA) and untreated short SGA controls. J. Clin. Endocrinol. Metab. 2007, 92:160-165.
    • (2007) J. Clin. Endocrinol. Metab. , vol.92 , pp. 160-165
    • van Dijk, M.1    Bannink, E.M.2    van Pareren, Y.K.3    Mulder, P.G.4    Hokken-Koelega, A.C.5
  • 45
    • 70349254743 scopus 로고    scopus 로고
    • Impact of growth hormone therapy on adult height of children born small for gestational age
    • Maiorana A., Cianfarani S. Impact of growth hormone therapy on adult height of children born small for gestational age. Pediatrics 2009, 124:e519-e531.
    • (2009) Pediatrics , vol.124
    • Maiorana, A.1    Cianfarani, S.2
  • 46
    • 61449233146 scopus 로고    scopus 로고
    • Growth response to an individualized versus fixed dose GH treatment in short children born small for gestational age: the OPTIMA study
    • Jung H., Land C., Nicolay C., De Schepper J., Blum W.F., Schönau E. Growth response to an individualized versus fixed dose GH treatment in short children born small for gestational age: the OPTIMA study. Eur. J. Endocrinol. 2009, 160:149-156.
    • (2009) Eur. J. Endocrinol. , vol.160 , pp. 149-156
    • Jung, H.1    Land, C.2    Nicolay, C.3    De Schepper, J.4    Blum, W.F.5    Schönau, E.6
  • 47
    • 15444361239 scopus 로고    scopus 로고
    • Three-year data from a comparative study with recombinant human growth hormone in the treatment of short stature in young children with intrauterine growth retardation
    • Fjellestad-Paulsen A., Czernichow P., Brauner R., et al. Three-year data from a comparative study with recombinant human growth hormone in the treatment of short stature in young children with intrauterine growth retardation. Acta Paediatr. 1998, 87:511-517.
    • (1998) Acta Paediatr. , vol.87 , pp. 511-517
    • Fjellestad-Paulsen, A.1    Czernichow, P.2    Brauner, R.3
  • 48
    • 0033305653 scopus 로고    scopus 로고
    • Skeletal features and growth patterns in 14 patients with haploinsufficiency of SHOX: implications for the development of Turner syndrome
    • Kosho T., Muroya K., Nagai T., et al. Skeletal features and growth patterns in 14 patients with haploinsufficiency of SHOX: implications for the development of Turner syndrome. J. Clin. Endocrinol. Metab. 1999, 84:4613-4621.
    • (1999) J. Clin. Endocrinol. Metab. , vol.84 , pp. 4613-4621
    • Kosho, T.1    Muroya, K.2    Nagai, T.3
  • 49
    • 0033304838 scopus 로고    scopus 로고
    • Growth retardation in Turner syndrome: aneuploidy, rather than specific gene loss, may explain growth failure
    • Haverkamp F., Wölfle J., Zerres K., et al. Growth retardation in Turner syndrome: aneuploidy, rather than specific gene loss, may explain growth failure. J. Clin. Endocrinol. Metab. 1999, 84:4578-4582.
    • (1999) J. Clin. Endocrinol. Metab. , vol.84 , pp. 4578-4582
    • Haverkamp, F.1    Wölfle, J.2    Zerres, K.3
  • 50
    • 0031991527 scopus 로고    scopus 로고
    • Growth hormone therapy of Turner's syndrome: beneficial effect on adult height
    • Rosenfeld R.G., Attie K.M., Frane J., et al. Growth hormone therapy of Turner's syndrome: beneficial effect on adult height. J. Pediatr. 1998, 132:319-324.
    • (1998) J. Pediatr. , vol.132 , pp. 319-324
    • Rosenfeld, R.G.1    Attie, K.M.2    Frane, J.3
  • 51
    • 0033305178 scopus 로고    scopus 로고
    • Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial
    • Sas T.C., de Muinck Keizer-Schrama S.M., Stijnen T., et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J. Clin. Endocrinol. Metab. 1999, 84:4607-4612.
    • (1999) J. Clin. Endocrinol. Metab. , vol.84 , pp. 4607-4612
    • Sas, T.C.1    de Muinck Keizer-Schrama, S.M.2    Stijnen, T.3
  • 52
    • 0036920811 scopus 로고    scopus 로고
    • Effect of discontinuation of long-term growth hormone treatment on carbohydrate metabolism and risk factors for cardiovascular disease in girls with Turner syndrome
    • van Pareren Y.K., De Muinck Keizer-Schrama S.M., Stijnen T., Sas T.C., Drop S.L. Effect of discontinuation of long-term growth hormone treatment on carbohydrate metabolism and risk factors for cardiovascular disease in girls with Turner syndrome. J. Clin. Endocrinol. Metab. 2002, 87:5442-5448.
    • (2002) J. Clin. Endocrinol. Metab. , vol.87 , pp. 5442-5448
    • van Pareren, Y.K.1    De Muinck Keizer-Schrama, S.M.2    Stijnen, T.3    Sas, T.C.4    Drop, S.L.5
  • 53
    • 18344393262 scopus 로고    scopus 로고
    • Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height
    • Quigley C.A., Crowe B.J., Anglin D.G., Chipman J.J. Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J. Clin. Endocrinol. Metab. 2002, 87:2033-2041.
    • (2002) J. Clin. Endocrinol. Metab. , vol.87 , pp. 2033-2041
    • Quigley, C.A.1    Crowe, B.J.2    Anglin, D.G.3    Chipman, J.J.4
  • 54
    • 0037340318 scopus 로고    scopus 로고
    • Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens
    • van Pareren Y.K., de Muinck Keizer-Schrama S.M., Stijnen T., et al. Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J. Clin. Endocrinol. Metab. 2003, 88:1119-1125.
    • (2003) J. Clin. Endocrinol. Metab. , vol.88 , pp. 1119-1125
    • van Pareren, Y.K.1    de Muinck Keizer-Schrama, S.M.2    Stijnen, T.3
  • 55
    • 0141787972 scopus 로고    scopus 로고
    • Late or delayed induced or spontaneous puberty in girls with Turner syndrome treated with growth hormone does not affect final height
    • Belgian Study Group for Pediatric Endocrinology
    • Massa G., Heinrichs C., Verlinde S., et al. Late or delayed induced or spontaneous puberty in girls with Turner syndrome treated with growth hormone does not affect final height. J. Clin. Endocrinol. Metab. 2003, 88:4168-4174. Belgian Study Group for Pediatric Endocrinology.
    • (2003) J. Clin. Endocrinol. Metab. , vol.88 , pp. 4168-4174
    • Massa, G.1    Heinrichs, C.2    Verlinde, S.3
  • 56
    • 0034530904 scopus 로고    scopus 로고
    • Kabi International Growth Study, prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. KIGS International Board. Kabi International Growth Study
    • KIGS International Board
    • Ranke M.B., Lindberg A., Chatelain P., et al. Kabi International Growth Study, prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. KIGS International Board. Kabi International Growth Study. J. Clin. Endocrinol. Metab. 2000, 85:4212-4218. KIGS International Board.
    • (2000) J. Clin. Endocrinol. Metab. , vol.85 , pp. 4212-4218
    • Ranke, M.B.1    Lindberg, A.2    Chatelain, P.3
  • 57
    • 21244448056 scopus 로고    scopus 로고
    • Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian Randomized Controlled Trial
    • The Canadian Growth Hormone Advisory Committee.
    • The Canadian Growth Hormone Advisory Committee Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian Randomized Controlled Trial. J. Clin. Endocrinol. Metab. 2005, 90:3360-3366.
    • (2005) J. Clin. Endocrinol. Metab. , vol.90 , pp. 3360-3366
  • 58
    • 34548804590 scopus 로고    scopus 로고
    • Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial
    • Davenport M.L., Crowe B.J., Travers S.H., et al. Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial. J. Clin. Endocrinol. Metab. 2007, 92:3406-3416.
    • (2007) J. Clin. Endocrinol. Metab. , vol.92 , pp. 3406-3416
    • Davenport, M.L.1    Crowe, B.J.2    Travers, S.H.3
  • 59
    • 17244381641 scopus 로고    scopus 로고
    • The role of insulin-like growth factor I monitoring in growth hormone-treated children
    • Park P., Cohen P. The role of insulin-like growth factor I monitoring in growth hormone-treated children. Horm. Res. 2004, 62(Suppl. 1):59-65.
    • (2004) Horm. Res. , vol.62 , Issue.SUPPL. 1 , pp. 59-65
    • Park, P.1    Cohen, P.2
  • 60
    • 77749315758 scopus 로고    scopus 로고
    • Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome
    • Menke L.A., Sas T.C., de Muinck Keizer-Schrama S.M., et al. Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome. J. Clin. Endocrinol. Metab. 2010, 95:1151-1160.
    • (2010) J. Clin. Endocrinol. Metab. , vol.95 , pp. 1151-1160
    • Menke, L.A.1    Sas, T.C.2    de Muinck Keizer-Schrama, S.M.3
  • 62
    • 0026073598 scopus 로고
    • Noonan's syndrome: abnormalities of the growth hormone/IGF-I axis and the response to treatment with human biosynthetic growth hormone
    • Ahmed M.L., Foot A.B., Edge J.A., Lamkin V.A., Savage M.O., Dunger D.B. Noonan's syndrome: abnormalities of the growth hormone/IGF-I axis and the response to treatment with human biosynthetic growth hormone. Acta Paediatr. Scand. 1991, 80:446-450.
    • (1991) Acta Paediatr. Scand. , vol.80 , pp. 446-450
    • Ahmed, M.L.1    Foot, A.B.2    Edge, J.A.3    Lamkin, V.A.4    Savage, M.O.5    Dunger, D.B.6
  • 63
    • 0029865254 scopus 로고    scopus 로고
    • Growth hormone treatment in Noonan syndrome: the National Cooperative Growth Study experience
    • Romano A.A., Blethen S.L., Dana K., Noto R.A. Growth hormone treatment in Noonan syndrome: the National Cooperative Growth Study experience. J. Pediatr. 1996, 128:S18-S21.
    • (1996) J. Pediatr. , vol.128
    • Romano, A.A.1    Blethen, S.L.2    Dana, K.3    Noto, R.A.4
  • 64
    • 0035008529 scopus 로고    scopus 로고
    • Growth hormone therapy and growth in children with Noonan's syndrome: results of 3 years' follow-up
    • Macfarlane C.E., Brown D.C., Johnston L.B., et al. Growth hormone therapy and growth in children with Noonan's syndrome: results of 3 years' follow-up. J. Clin. Endocrinol. Metab. 2001, 86:1953-1956.
    • (2001) J. Clin. Endocrinol. Metab. , vol.86 , pp. 1953-1956
    • Macfarlane, C.E.1    Brown, D.C.2    Johnston, L.B.3
  • 65
    • 42449084089 scopus 로고    scopus 로고
    • Response to growth hormone treatment and final height in Noonan syndrome in a large cohort of patients in the KIGS database
    • Raaijmakers R., Noordam C., Karagiannis G., et al. Response to growth hormone treatment and final height in Noonan syndrome in a large cohort of patients in the KIGS database. J. Pediatr. Endocrinol. Metab. 2008, 21:267-273.
    • (2008) J. Pediatr. Endocrinol. Metab. , vol.21 , pp. 267-273
    • Raaijmakers, R.1    Noordam, C.2    Karagiannis, G.3
  • 66
    • 0035021887 scopus 로고    scopus 로고
    • Short stature in Noonan syndrome: response to growth hormone therapy
    • Group tU
    • Kirk J.M., Betts P.R., Butler G.E., et al. Short stature in Noonan syndrome: response to growth hormone therapy. Arch. Dis. Child. 2001, 84:440-443. Group tU.
    • (2001) Arch. Dis. Child. , vol.84 , pp. 440-443
    • Kirk, J.M.1    Betts, P.R.2    Butler, G.E.3
  • 67
    • 53249131216 scopus 로고    scopus 로고
    • Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11
    • Noordam C., Peer P.G., Francois I., De Schepper J., van den Burgt I., Otten B.J. Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11. Eur. J. Endocrinol. 2008, 159:203-208.
    • (2008) Eur. J. Endocrinol. , vol.159 , pp. 203-208
    • Noordam, C.1    Peer, P.G.2    Francois, I.3    De Schepper, J.4    van den Burgt, I.5    Otten, B.J.6
  • 68
    • 73849105803 scopus 로고    scopus 로고
    • GH therapy in Noonan syndrome: review of final height data
    • Dahlgren J. GH therapy in Noonan syndrome: review of final height data. Horm. Res. 2009, 72(Suppl. 2):46-48.
    • (2009) Horm. Res. , vol.72 , Issue.SUPPL. 2 , pp. 46-48
    • Dahlgren, J.1
  • 69
    • 67650263893 scopus 로고    scopus 로고
    • Growth response, near-adult height, and patterns of growth and puberty in patients with Noonan syndrome treated with growth hormone
    • Romano A.A., Dana K., Bakker B., et al. Growth response, near-adult height, and patterns of growth and puberty in patients with Noonan syndrome treated with growth hormone. J. Clin. Endocrinol. Metab. 2009, 94:2338-2344.
    • (2009) J. Clin. Endocrinol. Metab. , vol.94 , pp. 2338-2344
    • Romano, A.A.1    Dana, K.2    Bakker, B.3
  • 70
    • 39049160669 scopus 로고    scopus 로고
    • Growth hormone treatment and fat redistribution in children born small for gestational age
    • De Schepper J., Thomas M., Beckers D., Craen M., Maes M., de Zegher F. Growth hormone treatment and fat redistribution in children born small for gestational age. J. Pediatr. 2008, 152:327-330.
    • (2008) J. Pediatr. , vol.152 , pp. 327-330
    • De Schepper, J.1    Thomas, M.2    Beckers, D.3    Craen, M.4    Maes, M.5    de Zegher, F.6
  • 71
    • 31744448841 scopus 로고    scopus 로고
    • Food intake of children with short stature born small for gestational age before and during a randomized GH trial
    • Boonstra V.H., Arends N.J., Stijnen T., Blum W.F., Akkerman O., Hokken-Koelega A.C. Food intake of children with short stature born small for gestational age before and during a randomized GH trial. Horm. Res. 2006, 65:23-30.
    • (2006) Horm. Res. , vol.65 , pp. 23-30
    • Boonstra, V.H.1    Arends, N.J.2    Stijnen, T.3    Blum, W.F.4    Akkerman, O.5    Hokken-Koelega, A.C.6
  • 72
    • 77952777084 scopus 로고    scopus 로고
    • Growth hormone therapy in short children born small for gestational age: effects on abdominal fat partitioning and circulating follistatin and high-molecular-weight adiponectin
    • Ibáñez L., Lopez-Bermejo A., Díaz M., Jaramillo A., Marín S., de Zegher F. Growth hormone therapy in short children born small for gestational age: effects on abdominal fat partitioning and circulating follistatin and high-molecular-weight adiponectin. J. Clin. Endocrinol. Metab. 2010, 95:2234-2239.
    • (2010) J. Clin. Endocrinol. Metab. , vol.95 , pp. 2234-2239
    • Ibáñez, L.1    Lopez-Bermejo, A.2    Díaz, M.3    Jaramillo, A.4    Marín, S.5    de Zegher, F.6
  • 73
    • 73949159311 scopus 로고    scopus 로고
    • The PPAR-gamma Pro12Ala polymorphism associates with weight gain during GH-treatment in short children born small for gestational age
    • de Kort S.W., Hokken-Koelega A.C. The PPAR-gamma Pro12Ala polymorphism associates with weight gain during GH-treatment in short children born small for gestational age. Eur. J. Endocrinol. 2010, 162:49-52.
    • (2010) Eur. J. Endocrinol. , vol.162 , pp. 49-52
    • de Kort, S.W.1    Hokken-Koelega, A.C.2
  • 74
    • 33751539823 scopus 로고    scopus 로고
    • The effects of growth hormone treatment on bone mineral density and body composition in girls with turner syndrome
    • Ari M., Bakalov V.K., Hil S., Bondy C.A. The effects of growth hormone treatment on bone mineral density and body composition in girls with turner syndrome. J. Clin. Endocrinol. Metab. 2006, 91:4302-4305.
    • (2006) J. Clin. Endocrinol. Metab. , vol.91 , pp. 4302-4305
    • Ari, M.1    Bakalov, V.K.2    Hil, S.3    Bondy, C.A.4
  • 75
    • 45149088442 scopus 로고    scopus 로고
    • Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome
    • Wooten N., Bakalov V.K., Hill S., Bondy C.A. Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome. J. Clin. Endocrinol. Metab. 2008, 93:2109-2114.
    • (2008) J. Clin. Endocrinol. Metab. , vol.93 , pp. 2109-2114
    • Wooten, N.1    Bakalov, V.K.2    Hill, S.3    Bondy, C.A.4
  • 76
    • 0032956687 scopus 로고    scopus 로고
    • Carbohydrate and lipid metabolism during various growth hormone dosing regimens in girls with Turner syndrome. Dutch Working Group on Growth Hormone
    • van Teunenbroek A., de Muinck Keizer-Schrama S.M., Aanstoot H.J., Stijnen T., Hoogerbrugge N., Drop S.L. Carbohydrate and lipid metabolism during various growth hormone dosing regimens in girls with Turner syndrome. Dutch Working Group on Growth Hormone. Metabolism 1999, 48:7-14.
    • (1999) Metabolism , vol.48 , pp. 7-14
    • van Teunenbroek, A.1    de Muinck Keizer-Schrama, S.M.2    Aanstoot, H.J.3    Stijnen, T.4    Hoogerbrugge, N.5    Drop, S.L.6
  • 77
    • 34548662418 scopus 로고    scopus 로고
    • Long-term effects of growth hormone (GH) treatment on body composition and bone mineral density in short children born small-for-gestational-age: six-year follow-up of a randomized controlled GH trial
    • Willemsen R.H., Arends N.J., Bakker-van Waarde W.M., et al. Long-term effects of growth hormone (GH) treatment on body composition and bone mineral density in short children born small-for-gestational-age: six-year follow-up of a randomized controlled GH trial. Clin. Endocrinol. (Oxf.) 2007, 67:485-492.
    • (2007) Clin. Endocrinol. (Oxf.) , vol.67 , pp. 485-492
    • Willemsen, R.H.1    Arends, N.J.2    Bakker-van Waarde, W.M.3
  • 78
    • 84883204190 scopus 로고    scopus 로고
    • Bone mineral assessment in patients with Prader-Willi syndrome
    • Salles J., Lounis N., Diene G., Conte-Auriol F., Moulin P., Tauber M. Bone mineral assessment in patients with Prader-Willi syndrome. Bone 2007, 40(Suppl 1):275.
    • (2007) Bone , vol.40 , Issue.SUPPL 1 , pp. 275
    • Salles, J.1    Lounis, N.2    Diene, G.3    Conte-Auriol, F.4    Moulin, P.5    Tauber, M.6
  • 79
    • 35348913162 scopus 로고    scopus 로고
    • Similar effects of long-term exogenous growth hormone (GH) on bone and muscle parameters: a pQCT study of GH-deficient and small-for-gestational-age (SGA) children
    • Schweizer R., Martin D.D., Haase M., et al. Similar effects of long-term exogenous growth hormone (GH) on bone and muscle parameters: a pQCT study of GH-deficient and small-for-gestational-age (SGA) children. Bone 2007, 41:875-881.
    • (2007) Bone , vol.41 , pp. 875-881
    • Schweizer, R.1    Martin, D.D.2    Haase, M.3
  • 80
    • 33645330427 scopus 로고    scopus 로고
    • Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy
    • Mazziotti G., Bianchi A., Bonadonna S., et al. Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J. Bone Miner. Res. 2006, 21:520-528.
    • (2006) J. Bone Miner. Res. , vol.21 , pp. 520-528
    • Mazziotti, G.1    Bianchi, A.2    Bonadonna, S.3
  • 82
    • 0142095035 scopus 로고    scopus 로고
    • Acquisition of bone mass in normal individuals and in patients with growth hormone deficiency
    • Baroncelli G.I., Bertelloni S., Sodini F., Saggese G. Acquisition of bone mass in normal individuals and in patients with growth hormone deficiency. J. Pediatr. Endocrinol. Metab. 2003, 16(Suppl. 2):327-335.
    • (2003) J. Pediatr. Endocrinol. Metab. , vol.16 , Issue.SUPPL. 2 , pp. 327-335
    • Baroncelli, G.I.1    Bertelloni, S.2    Sodini, F.3    Saggese, G.4
  • 83
    • 0036424524 scopus 로고    scopus 로고
    • The psychosocial consequences of short stature: a review of the evidence
    • Sandberg D.E., Voss L.D. The psychosocial consequences of short stature: a review of the evidence. Best Pract. Res. Clin. Endocrinol. Metab. 2002, 16:449-463.
    • (2002) Best Pract. Res. Clin. Endocrinol. Metab. , vol.16 , pp. 449-463
    • Sandberg, D.E.1    Voss, L.D.2
  • 85
    • 11844293088 scopus 로고    scopus 로고
    • Height and social adjustment: are extremes a cause for concern and action?
    • Sandberg D.E., Bukowski W.M., Fung C.M., Noll R.B. Height and social adjustment: are extremes a cause for concern and action?. Pediatrics 2004, 114:744-750.
    • (2004) Pediatrics , vol.114 , pp. 744-750
    • Sandberg, D.E.1    Bukowski, W.M.2    Fung, C.M.3    Noll, R.B.4
  • 86
    • 8744282738 scopus 로고    scopus 로고
    • Intelligence and psychosocial functioning during long-term growth hormone therapy in children born small for gestational age
    • van Pareren Y.K., Duivenvoorden H.J., Slijper F.S., Koot H.M., Hokken-Koelega A.C. Intelligence and psychosocial functioning during long-term growth hormone therapy in children born small for gestational age. J. Clin. Endocrinol. Metab. 2004, 89:5295-5302.
    • (2004) J. Clin. Endocrinol. Metab. , vol.89 , pp. 5295-5302
    • van Pareren, Y.K.1    Duivenvoorden, H.J.2    Slijper, F.S.3    Koot, H.M.4    Hokken-Koelega, A.C.5
  • 88
    • 33747343922 scopus 로고    scopus 로고
    • Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment
    • Bannink E.M., van Doorn J., Stijnen T., Drop S.L., de Muinck Keizer-Schrama S.M. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment. Clin. Endocrinol. (Oxf.) 2006, 65:310-319.
    • (2006) Clin. Endocrinol. (Oxf.) , vol.65 , pp. 310-319
    • Bannink, E.M.1    van Doorn, J.2    Stijnen, T.3    Drop, S.L.4    de Muinck Keizer-Schrama, S.M.5
  • 89
    • 24344434575 scopus 로고    scopus 로고
    • Safety of growth hormone treatment in pediatric patients with idiopathic short stature
    • Quigley C.A., Gill A.M., Crowe B.J., et al. Safety of growth hormone treatment in pediatric patients with idiopathic short stature. J. Clin. Endocrinol. Metab. 2005, 90:5188-5196.
    • (2005) J. Clin. Endocrinol. Metab. , vol.90 , pp. 5188-5196
    • Quigley, C.A.1    Gill, A.M.2    Crowe, B.J.3
  • 90
    • 44949248999 scopus 로고    scopus 로고
    • Recombinant growth hormone for idiopathic short stature in children and adolescents
    • Bryant J., Cave C., Milne R. Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst. Rev. 2003, 4:CD004440.
    • (2003) Cochrane Database Syst. Rev. , vol.4
    • Bryant, J.1    Cave, C.2    Milne, R.3
  • 92
  • 93
    • 0026008824 scopus 로고
    • Fetal and infant growth and impaired glucose tolerance at age 64
    • Hales C.N., Barker D.J., Clark P.M., et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ 1991, 303:1019-1022.
    • (1991) BMJ , vol.303 , pp. 1019-1022
    • Hales, C.N.1    Barker, D.J.2    Clark, P.M.3
  • 95
    • 0027529974 scopus 로고
    • Type 2 (noninsulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth
    • Barker D.J., Hales C.N., Fall C.H., Osmond C., Phipps K., Clark P.M. Type 2 (noninsulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993, 36:62-67.
    • (1993) Diabetologia , vol.36 , pp. 62-67
    • Barker, D.J.1    Hales, C.N.2    Fall, C.H.3    Osmond, C.4    Phipps, K.5    Clark, P.M.6
  • 96
    • 0036245664 scopus 로고    scopus 로고
    • Growth hormone therapy and its relationship to insulin resistance, glucose intolerance and diabetes mellitus: a review of recent evidence
    • Jeffcoate W. Growth hormone therapy and its relationship to insulin resistance, glucose intolerance and diabetes mellitus: a review of recent evidence. Drug Saf. 2002, 25:199-212.
    • (2002) Drug Saf. , vol.25 , pp. 199-212
    • Jeffcoate, W.1
  • 97
    • 66149101010 scopus 로고    scopus 로고
    • Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations
    • Friedrich N., Haring R., Nauck M., et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J. Clin. Endocrinol. Metab. 2009, 94:1732-1739.
    • (2009) J. Clin. Endocrinol. Metab. , vol.94 , pp. 1732-1739
    • Friedrich, N.1    Haring, R.2    Nauck, M.3
  • 98
    • 0036312704 scopus 로고    scopus 로고
    • Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study
    • Sklar C.A., Mertens A.C., Mitby P., et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J. Clin. Endocrinol. Metab. 2002, 87:3136-3141.
    • (2002) J. Clin. Endocrinol. Metab. , vol.87 , pp. 3136-3141
    • Sklar, C.A.1    Mertens, A.C.2    Mitby, P.3
  • 99
    • 33750080457 scopus 로고    scopus 로고
    • Cancers associated with acromegaly
    • Jenkins P.J. Cancers associated with acromegaly. Neuroendocrinology 2006, 83:218-223.
    • (2006) Neuroendocrinology , vol.83 , pp. 218-223
    • Jenkins, P.J.1
  • 100
    • 0345828935 scopus 로고    scopus 로고
    • Clinical pharmacological aspects of growth hormone administration
    • Laursen T. Clinical pharmacological aspects of growth hormone administration. Growth Horm. IGF Res. 2004, 14:16-44.
    • (2004) Growth Horm. IGF Res. , vol.14 , pp. 16-44
    • Laursen, T.1
  • 101
    • 0026014288 scopus 로고
    • Human growth hormone replacement therapy: pharmacological and clinical aspects
    • Jørgensen J.O. Human growth hormone replacement therapy: pharmacological and clinical aspects. Endocr. Rev. 1991, 12:189-207.
    • (1991) Endocr. Rev. , vol.12 , pp. 189-207
    • Jørgensen, J.O.1
  • 103
    • 0035048752 scopus 로고    scopus 로고
    • Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults
    • Laursen T., Gravholt C.H., Heickendorff L., et al. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. J. Clin. Endocrinol. Metab. 2001, 86:1222-1228.
    • (2001) J. Clin. Endocrinol. Metab. , vol.86 , pp. 1222-1228
    • Laursen, T.1    Gravholt, C.H.2    Heickendorff, L.3
  • 104
    • 40949136609 scopus 로고    scopus 로고
    • Long-acting forms of growth hormone-releasing hormone and growth hormone: effects in normal volunteers and adults with growth hormone deficiency
    • Clemmons D.R. Long-acting forms of growth hormone-releasing hormone and growth hormone: effects in normal volunteers and adults with growth hormone deficiency. Horm. Res. 2007, 68(Suppl. 5):178-181.
    • (2007) Horm. Res. , vol.68 , Issue.SUPPL. 5 , pp. 178-181
    • Clemmons, D.R.1
  • 105
    • 3242666740 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children
    • Kemp S., Fielder P.J., Attie K.M., et al. Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children. J. Clin. Endocrinol. Metab. 2004, 89:3234-3240.
    • (2004) J. Clin. Endocrinol. Metab. , vol.89 , pp. 3234-3240
    • Kemp, S.1    Fielder, P.J.2    Attie, K.M.3
  • 106
    • 0036290740 scopus 로고    scopus 로고
    • A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency
    • Silverman B.L., Blethen S.L., Reiter E.O., Attie K.M., Neuwirth R.B., Ford K.M. A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency. J. Pediatr. Endocrinol. Metab. 2002, 15(Suppl. 2):715-722.
    • (2002) J. Pediatr. Endocrinol. Metab. , vol.15 , Issue.SUPPL. 2 , pp. 715-722
    • Silverman, B.L.1    Blethen, S.L.2    Reiter, E.O.3    Attie, K.M.4    Neuwirth, R.B.5    Ford, K.M.6
  • 107
    • 77954900288 scopus 로고    scopus 로고
    • Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile
    • Rasmussen M.H., Bysted B.V., Anderson T.W., Klitgaard T., Madsen J. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile. J. Clin. Endocrinol. Metab. 2010, 95:3411-3417.
    • (2010) J. Clin. Endocrinol. Metab. , vol.95 , pp. 3411-3417
    • Rasmussen, M.H.1    Bysted, B.V.2    Anderson, T.W.3    Klitgaard, T.4    Madsen, J.5
  • 108
    • 78649237780 scopus 로고    scopus 로고
    • Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile
    • Rasmussen M.H., Jensen L., Anderson T.W., Klitgaard T., Madsen J. Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile. Clin. Endocrinol. (Oxf.) 2010, 73:769-776.
    • (2010) Clin. Endocrinol. (Oxf.) , vol.73 , pp. 769-776
    • Rasmussen, M.H.1    Jensen, L.2    Anderson, T.W.3    Klitgaard, T.4    Madsen, J.5
  • 109
    • 79952289185 scopus 로고    scopus 로고
    • Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with GH deficiency
    • Søndergaard E., Klose M., Hansen M., et al. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with GH deficiency. J. Clin. Endocrinol. Metab. 2011, 96:681-688.
    • (2011) J. Clin. Endocrinol. Metab. , vol.96 , pp. 681-688
    • Søndergaard, E.1    Klose, M.2    Hansen, M.3
  • 110
    • 28744459194 scopus 로고    scopus 로고
    • Genentech adult growth hormone deficiency study group, efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency
    • Hoffman A.R., Biller B.M., Cook D., et al. Genentech adult growth hormone deficiency study group, efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. J. Clin. Endocrinol. Metab. 2005, 90:6431-6440.
    • (2005) J. Clin. Endocrinol. Metab. , vol.90 , pp. 6431-6440
    • Hoffman, A.R.1    Biller, B.M.2    Cook, D.3
  • 111
    • 0030007487 scopus 로고    scopus 로고
    • Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: I. Effects on insulin-like growth factor-I (IGF-I), GH and IGF binding proteins, and glucose homeostasis
    • Johansson J.O., Oscarsson J., Bjarnason R., Bengtsson B.A. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: I. Effects on insulin-like growth factor-I (IGF-I), GH and IGF binding proteins, and glucose homeostasis. Metabolism 1996, 45:362-369.
    • (1996) Metabolism , vol.45 , pp. 362-369
    • Johansson, J.O.1    Oscarsson, J.2    Bjarnason, R.3    Bengtsson, B.A.4
  • 112
    • 0025292432 scopus 로고
    • Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices
    • Jørgensen J.O., Møller N., Lauritzen T., Christiansen J.S. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices. J. Clin. Endocrinol. Metab. 1990, 70:1616-1623.
    • (1990) J. Clin. Endocrinol. Metab. , vol.70 , pp. 1616-1623
    • Jørgensen, J.O.1    Møller, N.2    Lauritzen, T.3    Christiansen, J.S.4
  • 113
    • 79957784185 scopus 로고    scopus 로고
    • French Acromegaly Registry. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry
    • Fieffe S., Morange I., Petrossians P., et al. French Acromegaly Registry. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur. J. Endocrinol. 2011, 164:877-884.
    • (2011) Eur. J. Endocrinol. , vol.164 , pp. 877-884
    • Fieffe, S.1    Morange, I.2    Petrossians, P.3
  • 114
    • 1442326975 scopus 로고    scopus 로고
    • Systemic complications of acromegaly: epidemiology, pathogenesis, and management
    • Colao A., Ferone D., Marzullo P., Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 2004, 25:102-152.
    • (2004) Endocr. Rev. , vol.25 , pp. 102-152
    • Colao, A.1    Ferone, D.2    Marzullo, P.3    Lombardi, G.4
  • 116
    • 0035048752 scopus 로고    scopus 로고
    • Long-term effects of continuous subcutaneous (sc) infusion versus daily injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, bone and lipoprotein metabolism in GH-deficient adults
    • Laursen T., Gravholt C.H., Heickendorff L., et al. Long-term effects of continuous subcutaneous (sc) infusion versus daily injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, bone and lipoprotein metabolism in GH-deficient adults. J. Clin. Endocrinol. Metab. 2001, 86:1222-1228.
    • (2001) J. Clin. Endocrinol. Metab. , vol.86 , pp. 1222-1228
    • Laursen, T.1    Gravholt, C.H.2    Heickendorff, L.3
  • 119
    • 7944239392 scopus 로고    scopus 로고
    • Growth hormone (GH) provocation tests and the response to GH treatment in GH deficiency
    • Cole T.J., Hindmarsh P.C., Dunger D.B. Growth hormone (GH) provocation tests and the response to GH treatment in GH deficiency. Arch. Dis. Child. 2004, 89:1024-1027.
    • (2004) Arch. Dis. Child. , vol.89 , pp. 1024-1027
    • Cole, T.J.1    Hindmarsh, P.C.2    Dunger, D.B.3
  • 120
    • 16344387901 scopus 로고    scopus 로고
    • Patient outcomes in the GH Monitor: the effect of delivery device on compliance and growth
    • Desrosiers P., O'Brien F., Blethen S. Patient outcomes in the GH Monitor: the effect of delivery device on compliance and growth. Pediatr. Endocrinol. Rev. 2005, 2(Suppl. 3):327-331.
    • (2005) Pediatr. Endocrinol. Rev. , vol.2 , Issue.SUPPL. 3 , pp. 327-331
    • Desrosiers, P.1    O'Brien, F.2    Blethen, S.3
  • 121
    • 38849149862 scopus 로고    scopus 로고
    • Monitoring of concordance in growth hormone therapy
    • Kapoor R.R., Burke S.A., Sparrow S.E., et al. Monitoring of concordance in growth hormone therapy. Arch. Dis. Child. 2008, 93:147-148.
    • (2008) Arch. Dis. Child. , vol.93 , pp. 147-148
    • Kapoor, R.R.1    Burke, S.A.2    Sparrow, S.E.3
  • 122
    • 0942266135 scopus 로고    scopus 로고
    • Long-term outcome of growth hormone therapy in children and adolescents
    • Lanes R. Long-term outcome of growth hormone therapy in children and adolescents. Treat. Endocrinol. 2004, 3:53-66.
    • (2004) Treat. Endocrinol. , vol.3 , pp. 53-66
    • Lanes, R.1
  • 124
    • 45849125438 scopus 로고    scopus 로고
    • Compliance and persistence in pediatric and adult patients receiving growth hormone therapy
    • Rosenfeld R.G., Bakker B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr. Pract. 2008, 14:143-154.
    • (2008) Endocr. Pract. , vol.14 , pp. 143-154
    • Rosenfeld, R.G.1    Bakker, B.2
  • 125
    • 41549148182 scopus 로고    scopus 로고
    • Observations of nonadherence to recombinant human growth hormone therapy in clinical practice
    • Haverkamp F., Johansson L., Dumas H., et al. Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. Clin. Ther. 2008, 30:307-316.
    • (2008) Clin. Ther. , vol.30 , pp. 307-316
    • Haverkamp, F.1    Johansson, L.2    Dumas, H.3
  • 126
    • 33845405556 scopus 로고    scopus 로고
    • Inhaled insulin (Exubera): combining efficacy and convenience
    • Bellary S., Barnett A.H. Inhaled insulin (Exubera): combining efficacy and convenience. Diab. Vasc. Dis. Res. 2006, 3:179-185.
    • (2006) Diab. Vasc. Dis. Res. , vol.3 , pp. 179-185
    • Bellary, S.1    Barnett, A.H.2
  • 127
    • 0033258165 scopus 로고    scopus 로고
    • Norditropin® SimpleXx- a liquid human growth hormone formulation, a pen system and an auto-insertion device
    • Müller J., Skakkebaek N.E., Jacobsen B., et al. Norditropin® SimpleXx-: a liquid human growth hormone formulation, a pen system and an auto-insertion device. Horm. Res. 1999, 51(Suppl. 3):109-112.
    • (1999) Horm. Res. , vol.51 , Issue.SUPPL. 3 , pp. 109-112
    • Müller, J.1    Skakkebaek, N.E.2    Jacobsen, B.3
  • 128
    • 0034956581 scopus 로고    scopus 로고
    • An open-label acceptability study of Norditropin SimpleXx - a new liquid growth hormone formulation
    • Stanhope R., Buchanan C., Butler G., et al. An open-label acceptability study of Norditropin SimpleXx - a new liquid growth hormone formulation. J. Pediatr. Endocrinol. Metab. 2001, 14:735-740.
    • (2001) J. Pediatr. Endocrinol. Metab. , vol.14 , pp. 735-740
    • Stanhope, R.1    Buchanan, C.2    Butler, G.3
  • 129
    • 0036042720 scopus 로고    scopus 로고
    • Acceptability of liquid human growth hormone (hGH) (Norditropin SimpleXx) in adults and children with growth hormone deficiency and children with chronic renal disease
    • Drent M.L., Jakobsdottir S., van Wijk J., et al. Acceptability of liquid human growth hormone (hGH) (Norditropin SimpleXx) in adults and children with growth hormone deficiency and children with chronic renal disease. Clin. Drug Investig. 2002, 22:633-638.
    • (2002) Clin. Drug Investig. , vol.22 , pp. 633-638
    • Drent, M.L.1    Jakobsdottir, S.2    van Wijk, J.3
  • 130
    • 0035458278 scopus 로고    scopus 로고
    • Effects of injection duration on site-pain intensity and bruising associated with subcutaneous heparin
    • Chan H. Effects of injection duration on site-pain intensity and bruising associated with subcutaneous heparin. J. Adv. Nurs. 2001, 35:882-892.
    • (2001) J. Adv. Nurs. , vol.35 , pp. 882-892
    • Chan, H.1
  • 134
    • 33645073012 scopus 로고    scopus 로고
    • Pain perception after subcutaneous injections of media containing different buffers
    • Laursen T., Hansen B., Fisker S. Pain perception after subcutaneous injections of media containing different buffers. Basic Clin. Pharmacol. Toxicol. 2006, 98:218-221.
    • (2006) Basic Clin. Pharmacol. Toxicol. , vol.98 , pp. 218-221
    • Laursen, T.1    Hansen, B.2    Fisker, S.3
  • 135
    • 0031845014 scopus 로고    scopus 로고
    • Pain perception following subcutaneous injections of citrate-buffered and phosphate-buffered epoetin alpha
    • Yu A.W., Leung C.B., Li P.K., et al. Pain perception following subcutaneous injections of citrate-buffered and phosphate-buffered epoetin alpha. Int. J. Artif. Organs 1998, 21:341-343.
    • (1998) Int. J. Artif. Organs , vol.21 , pp. 341-343
    • Yu, A.W.1    Leung, C.B.2    Li, P.K.3
  • 136
    • 0031745277 scopus 로고    scopus 로고
    • Multicentre survey on compliance with growth hormone therapy: what can be improved?
    • Oyarzabal M., Aliaga M., Chueca M., Echarte G., Ulied A. Multicentre survey on compliance with growth hormone therapy: what can be improved?. Acta Paediatr. 1998, 87:387-391.
    • (1998) Acta Paediatr. , vol.87 , pp. 387-391
    • Oyarzabal, M.1    Aliaga, M.2    Chueca, M.3    Echarte, G.4    Ulied, A.5
  • 137
    • 80055079375 scopus 로고    scopus 로고
    • The perception of pain after subcutaneous injection of five different medias containing different solutions for use in the dissolution human growth homone (GH) in healthy volunteers
    • Hansen B., Bojesen A., Laursen T. The perception of pain after subcutaneous injection of five different medias containing different solutions for use in the dissolution human growth homone (GH) in healthy volunteers. Horm. Res. 2002, 58(Suppl. 2):106.
    • (2002) Horm. Res. , vol.58 , Issue.SUPPL. 2 , pp. 106
    • Hansen, B.1    Bojesen, A.2    Laursen, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.